Physician profile
Raysa Redondo
NPI 1477034346
$3,304.56
in general payments reported to CMS, 2019-2025
16 companies · $2,682 in 2025
The $2,682 reported for 2025 was more than what 95% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $158 · 2024: $464 · 2025: $2,682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,203 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,203.07 |
| Education | $101.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $670.95 | 2023-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $523.67 | 2024-2025 | Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $505.34 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $504.80 | 2024-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Teva Pharmaceuticals USA, INC. | $325.56 | 2024-2025 | Austedo Xr, Uzedy |
| Alkermes, INC. | $242.01 | 2025 | Aristada, Lybalvi, Vivitrol |
| Almatica Pharma LLC | $116.23 | 2024-2025 | Loreev Xr |
| Axsome Therapeutics, INC. | $113.30 | 2023-2025 | Auvelity |
| Abbvie INC. | $84.19 | 2025 | |
| Lundbeck LLC | $44.33 | 2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $43.44 | 2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $37.36 | 2024 | Hetlioz, Fanapt |
| Supernus Pharmaceuticals, INC. | $33.73 | 2025 | Qelbree |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $22.89 | 2023 | |
| Braeburn INC. | $18.68 | 2025 | Brixadi |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $18.08 | 2023 | Spravato |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raysa Redondo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.